Celldex Therapeutics Inc (NASDAQ:CLDX)
| 15.40 Data as of Jun 18 |  -0.41 / -2.59%Today’s Change | 4.30 Today|||52-Week Range 16.48 | +129.51% Year-to-Date |
Latest CLDX News | Press Releases
| A Trio of Cancer Immunotherapy Innovators Jun 14 / MotleyFool.com | The Action Has Shifted Jun 11 / TheStreet.com |
| Good And Bad Breast Cancer Drugs Jun 14 / MotleyFool.com | Keep an Eye on the Close Jun 11 / TheStreet.com |
| Feels Like a Bear Market Jun 12 / TheStreet.com | Buying Is Improving Jun 11 / TheStreet.com |
| The Poor Action Continues Jun 12 / TheStreet.com | A Promising Platform for Cancer Immunotherapy Jun 10 / MotleyFool.com |
| More Signs of a Change Jun 12 / TheStreet.com |
Today’s Trading
| Previous close | 15.81 |
| Today’s open | 15.79 |
| Day’s range | 15.36 - 15.97 |
| Volume | 1,258,345 |
| Average volume (3 months) | 1,438,912 |
| Market cap | $1.3B |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/18/2013
Growth & Valuation
| Earnings growth (last year) | +9.73% |
| Earnings growth (this year) | +8.33% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +20.91% |
| P/E ratio | NM |
| Price/Sales | 34.57 |
| Price/Book | 10.62 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MGMistras Group Inc | +0.08 | +0.36% |
| FCSCFibrocell Science In... | +0.64 | +11.13% |
| UBICUBIC Inc | -0.17 | -2.42% |
| RPBIFResponse Biomedical ... | 0.00 | 0.00% |
Data as of 4:02pm ET, 06/18/2013
Financials
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $11.2M |
| Annual profit (last year) | -$59.1M |
| Net profit margin | -527.79% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Anthony S. Marucci, MBA |
CFO, Secretary, Treasurer & Senior Vice President Avery W. Catlin, MBA, CPA |
Corporate headquarters Needham, Massachusetts |
Forecasts
